Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Decatur, IL

BOSTON, Oct. 7, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, and SOFIE Biosciences (SOFIE), a national US manufacturer and developer of PET radiopharmaceuticals, announce that Neuraceq® is now available from SOFIE's radiopharmaceutical manufacturing site in Decatur, Illinois. The first doses were produced on September 23^rd, 2025.

Neuraceq® is an FDA-approved radioactive diagnostic drug indicated for the detection of amyloid plaques in the brain of adult patients with cognitive impairment symptomology who are being evaluated for Alzheimer's disease and other causes of cognitive decline.

By expanding into this new geography, Neuraceq® is now available to more patients, physicians, and imaging centers across Illinois and the greater Midwest.

"Expanding access to Neuraceq® ensures that physicians and patients navigating the evaluation of Alzheimer's disease have the advanced diagnostic support they need. As demand for amyloid PET imaging grows alongside anti-amyloid therapies and improved reimbursement pathways, the availability of Neuraceq® from Decatur, IL, marks a key milestone in broadening service across the Midwest and beyond. This achievement reflects our commitment to improving patient care, supporting healthcare providers, and delivering answers to individuals and families facing the challenges of cognitive decline," said Colleen Ruby, US Country Head and Chief Operating Officer, Americas and APAC of LMI, a Lantheus company.

"Expanding the SOFIE network is about more than just growth. Our Decatur, IL location represents a pivotal investment in the Midwest, enabling us to bring radiopharmaceuticals like Neuraceq® closer to communities, reducing wait times, and improving patient care across the region," said William Crisp, Vice President of Operations.

About Neuraceq® (florbetaben 18F)

Indications and Use

NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products.

CONTRAINDICATIONS: None 

WARNINGS AND PRECAUTIONS:

• Risk for Image Misinterpretation and other Errors: NEURACEQ Risk of Image Misinterpretation and Other Errors: Image interpretation errors have been observed. [see Section 5.1 of the full prescribing information]
• Radiation Risk: NEURACEQ, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration in the full prescribing information].

ADVERSE REACTIONS:

The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/application site erythema (1.7%), and injection site irritation (1.1%).

For more information please visit: Neuraceq.com

About Life Molecular Imaging (LMI)

Life Molecular Imaging (LMI), a Lantheus company, is dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. To learn more about LMI, please visit https://life-mi.com.

About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland and Sweden, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit www.lantheus.com.

Contacts
Investor Relations: Mark Kinarney
Vice President, Investor Relations
978-671-8842
[email protected]

Media: Melissa Downs
Executive Director, External Communications
646-975-2533
[email protected]

SOURCE Life Molecular Imaging